TNF Pharmaceuticals, Inc. (TNFA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product revenue | - | - | - | - |
| Product cost of sales | - | - | - | - |
| Gross income | - | - | - | - |
| Administrative expenses | 894.297 | 841.685 | 1,104.13 | 1,020.312 |
| Series g warrant issuance expenses | - | - | - | - |
| Series f-1 warrant issuance expenses | - | - | - | - |
| Research and development expenses | 873.472 | 1,545.513 | 707.747 | 401.104 |
| Stock based compensation expenses | 104.854 | 84.636 | 13.762 | 439.627 |
| Series f-1 warrant issuance expenses | - | - | - | 539.097 |
| Series g warrant issuance expenses | - | - | - | 969.505 |
| Loss from operations | -1,872.623 | -2,471.834 | -1,825.639 | -3,369.645 |
| Loss on issuance of series f-1 convertible preferred stock | - | - | - | 3,737 |
| Loss on issuance of preferred stock | - | - | - | 5,109 |
| Gainlossonsalesofmarketablesecurities | - | - | 0.551 | -0.075 |
| Changeinfairvalueofmarketablesecurities | - | - | 4.746 | -0.076 |
| Gain (losses) on fair value of derivative liability | - | - | -356 | -72 |
| Casualtygainloss | - | - | 100 | - |
| Gain on sale of investments | - | 2.176 | - | - |
| Unrealized loss on marketable securities | - | -1.597 | - | - |
| (gain)/loss on sale of marketable securities | - | - | - | - |
| Interest and dividend income | 57.575 | 62.512 | 163.951 | 21.148 |
| Change in fair value of derivatives liabilities | 19 | 1,284 | - | - |
| Change in fair value of warrant liabilities | - | - | 17 | -2,701 |
| Loss on issuance of series g convertible preferred stock | - | - | - | - |
| Loss on issuance of series f-1 convertible preferred stock | - | - | - | - |
| Change in fair value of marketable securities | -0.147 | - | - | - |
| Total other (income)/expense | 76.428 | 1,347.091 | -103.752 | -6,196.003 |
| Loss before income tax | -1,796.195 | -1,124.743 | -1,929.391 | -9,565.648 |
| Income tax benefit | - | - | - | - |
| Net loss | -1,796.195 | -1,124.743 | -1,929.391 | -9,565.648 |
| Preferred stock dividends | 976.369 | 813.496 | 751.052 | 777.34 |
| Net loss attributable to common stockholders | -2,772.564 | -1,938.239 | -2,680.443 | -10,342.988 |
| Basic loss per common share | -0.18 | -0.36 | -1.11 | -4.54 |
| Diluted loss per common share | -0.18 | -0.36 | -1.11 | -4.54 |
| Weighted average basic common stock outstanding | 15,698,856 | 5,349,662 | 2,415,089 | 2,275,699 |
| Weighted average diluted common stock outstanding | 15,698,856 | 5,349,662 | 2,415,089 | 2,275,699 |